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A secondary RET mutation in the activation loop
conferring resistance to vandetanib
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Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic
lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to
treatment. The resistant tumor acquired a secondary mutation resulting in a serine-to-
phenylalanine substitution at codon 904 in the activation loop of the RET kinase domain. The
S904F mutation confers resistance to vandetanib by increasing the ATP afﬁnity and
autophosphorylation activity of RET kinase. A reduced interaction with the drug is also
observed in vitro for the S904F mutant by thermal shift assay. A crystal structure of the
S904F mutant reveals a small hydrophobic core around F904 likely to enhance basal kinase
activity by stabilizing an active conformer. Our ﬁndings indicate that missense mutations in
the activation loop of the kinase domain are able to increase kinase activity and confer drug
resistance through allosteric effects.
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Oncogenic ALK and ROS1 fusion-targeted therapy usingtype I tyrosine-kinase inhibitors (TKIs), which bind tothe ATP-binding cleft of kinases, is highly effective in
lung adenocarcinoma (LADC)1,2; however, such cancers inevi-
tably acquire resistance to targeted therapies, which severely
limits the efﬁcacy of cancer treatments. Secondary mutations that
cause amino acid substitutions in the kinase domain (KD),
including the gatekeeper and solvent-accessible regions, are an
important cause of resistance to various extents3. The identiﬁ-
cation of resistance mutations in ALK and ROS1 led to the
development of novel TKIs to overcome acquired resistance1,3,4.
Oncogenic fusions of the RET kinase gene are present in 1‒2%
of LADCs5,6, and are the subject of intense investigation. These
fusions are promising targets for the treatment of LADC7,8,
because of the availability of clinically active RET TKIs, such as
vandetanib and cabozantinib9. However, the mechanisms
underlying acquired resistance to RET TKIs in lung cancer
patients remain to be elucidated, and the molecular process by
which cancer cells acquire such resistance needs to be investi-
gated. Here we report the ﬁrst case of a secondary RET mutation
associated with resistance to the RET TKI vandetanib. The patient
described was enrolled into our clinical trial8, LURET (Lung
Cancer with RET Rearrangement Study; clinical trial registration
number: UMIN000010095, https://upload.umin.ac.jp/), which
investigates the efﬁcacy of vandetanib for the treatment of non-
small cell lung cancer (NSCLC) with oncogenic RET fusion. In
this trial, 19 RET fusion-positive cases were enrolled through
genetic screening of 1536 patients, and 17 eligible cases showed a
response rate of 53% and a progression-free survival period of
4–7 months8.
Results
Case report. A 57-year-old Japanese woman was referred to our
hospital with a nodule in her left lung that was detected in a
medical checkup. Bronchoscopic and mediastinoscopic exam-
inations revealed adenocarcinoma of the lung with mediastinal
lymph node metastases. The patient underwent concurrent che-
moradiotherapy with cisplatin and vinorelbine, resulting in a
partial response; however, 2 years later, multiple bone metastases
developed. Genetic examination revealed no mutation in EGFR.
The patient received second- to sixth-line chemotherapies con-
sisting of geﬁtinib, pemetrexed, docetaxel, gemcitabine, and S-1.
During sixth-line chemotherapy, the patient developed right
cervical lymphadenopathy (Fig. 1a and Supplementary Fig. 1),
and a biopsy of the lymph node revealed adenocarcinoma (Fig. 1b
and Supplementary Fig. 2a). Additional molecular testing for
RET, ALK, and ROS1 fusions was performed by LC-SCRUM
(Lung Cancer Genomic Screening Project for Individualized
Medicine in Japan)10. Reverse transcriptase-polymerase chain
reaction (RT-PCR) analysis of total RNA extracted from snap-
frozen biopsied tumor cells revealed a CCDC6-RET fusion and no
other fusions (Fig. 1c). The CCDC6-RET fusion led to the
expression of a fusion transcript in which exon 1 of CCCDC6 was
joined to exon 12 of RET. The CCDC6-RET fusion was validated
by identifying breakpoint junctions in genomic DNA
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Fig. 1 Identiﬁcation of a RET-S904F mutation conferring resistance to vandetanib. a Clinical course of the patient and axial chest computed tomographic
(CT) scan. (Upper) The blue line indicates the serum CEA level, and the orange line indicates the size of the target lesion (the right metastatic cervical
lymph node). The time points of the biopsy of metastatic lymph nodes are indicated by an arrowhead in Biopsy #1 and an arrow in Biopsy #2 (the details of
the clinical course are shown in Supplementary Fig. 1). (Lower) CT scan images of the metastatic lymph node as a target lesion. b Sanger sequencing
results of RT-PCR products from pretreatment specimens (Biopsy #1, pre) and specimens obtained at disease progression (Biopsy #2, pro). The same
CCDC6-RET fusion transcript in which exon 1 of CCCDC6 is joined to exon 15 of RET was expressed. c Histological ﬁndings of hematoxylin/eosin-stained
lymph node biopsy specimens obtained before treatment (Biopsy #1) and after disease progression (Biopsy #2). The identical pathological features are
shown. d Sanger sequencing of genomic-PCR and RT-PCR products from peripheral blood, pretreatment specimens (pre), and specimens obtained at
disease progression (pro). A mutation of cytosine to thymine at residue 2902 was detected only in the resistant tumor specimen. Genomic and RT-PCR
analysis was performed using a primer in CCDC6-exon 1 and a reverse primer in RET-exon 15. The detection of the substitution, which causes an amino acid
substitution of serine-to phenylalanine at codon 904 (in magenta), in genomic DNA and in the fusion transcript suggested that the mutation occurred on
the rearranged RET allele in the resistant tumor
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(Supplementary Fig. 2b). The patient was subsequently enrolled
into the LURET trial.
The patient showed a dramatic response to vandetanib, a type I
RET TKI, with reduction in her tumor size from 20 to 7 mm in
diameter at 12 weeks. This was consistent with a high-response
rate in the LURET study in CCDC6-RET–positive cases (5/6
cases, 83%)8. However, the patient developed a resistant tumor
with the same histological features and a CCDC6-RET fusion (C1;
R12) at 38 weeks (Fig. 1a–c, Supplementary Fig. 1 and Fig. 2a).
Given the high diversity of breakpoints for RET fusions11, the
identical genome structures of the breakpoint junctions (Supple-
mentary Fig. 2b) indicated that the resistant tumor originated
from the original tumor present before vandetanib treatment.
Discovery of a S904F secondary mutation in the RET kinase
domain. Targeted deep sequencing of cancer-related genes from
genomic DNA identiﬁed a serine-to-phenylalanine substitution at
codon 904 (S904F) in RET as the only non-synonymous mutation
in the resistant tumor; the baseline tumor samples contained no
non-synonymous mutations (Supplementary Fig. 3). Sanger
sequencing of RT-PCR products of fusion transcripts veriﬁed that
the S904F mutation occurred on the RET allele fused to the
CCDC6 locus (Fig. 1d). Whole-exome sequencing analysis
revealed four mutations speciﬁc to the resistant tumor, including
the RET-S904F mutation (Supplementary Fig. 3b). The lack of
reports connecting the three other mutated genes to drug resis-
tance prompted us to further study the RET-S904F mutation.
Vandetanib resistance is related to increased ATP afﬁnity and
autophosphorylation activity. The serine 904 residue is located
in between two autophosphorylation tyrosines Y900 and Y905
within the canonical activation loop (AL) of RET kinase; however,
it is not conserved among kinases (Supplementary Fig. 4).
Phosphorylation of an exogenously expressed S904F mutant of
CCDC6-RET in H1299 lung cancer cells, which do not express
endogenous RET6, was maintained at a higher vandetanib con-
centration (half-maximal inhibitory concentration [IC50] = 2.6
μM) than that in the wild-type CCDC6-RET protein (IC50 = 0.57
μM) (Fig. 2a). This ﬁnding was validated in another cell line, Ba/
F3, which grew in an interleukin 3 (IL3)-independent manner
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Fig. 2 Resistance to vandetanib by RET-S904F mutation. a Immunoblot analysis of the wild type and S904F mutant CCDC6-RET fusion proteins. (Left) An
expression vector encoding full-length wild type or S904F mutant CCDC6-RET cDNA was transiently introduced into H1299 lung cancer cells. After
exposure to the indicated concentrations of vandetanib for 6 h, phosphorylation at tyrosines 905 and 1015 were detected. The signal intensities, calculated
as the ratio of phosphorylated to total CCDC6-RET fusion proteins, are shown at the bottom. (Right) The experiment (shown on the left) was performed
separately three times (Supplementary Fig. 8). The graph shows the mean ratios of phospho-Ret (pTyr905) to total RET from three separate experiments
with standard deviations (shown as error bars). Concentrations showing statistical signiﬁcance (p< 0.05 by t-test) are marked with an asterisk. ACTB:
beta-actin. b Cell growth assay using IL3-independent Ba/F3 cells carrying lentivirally transduced CCDC6-RET cDNA with or without the S904F mutation.
Ba/F3 cells (2000 cells) were plated in quadruplicate in 96-well plates and treated with serially diluted vandetanib. After incubation for 72 h, cell viability
was measured using the CellTiter-Glo luminescent reagent with EnVision and the viability curves with standard deviations (shown as error bars) were
calculated with GraphPad Prism version 6.0. Reproducibility was conﬁrmed by performing the same experiment three times. c In vitro kinase assays.
Recombinant RET kinase domain (KD) (amino acids 658–1072) with or without the S904F mutation was expressed by baculovirus in Sf9 insect cells using
an N-terminal GST tag (gene accession number: NM_020630). The assay was initiated by addition of 32P-ATP to the reaction mixture and serially diluted
vandetanib, and the IGF1Rtide synthetic peptide was added as the substrate (KKKSPGEYVNIEFG). After incubation at 30 °C for 20min, the radioactivity
was measured in a TriLux scintillation counter after transferring the products onto a phosphocellulose P81 plate. IC50 values with 95% conﬁdence interval
were calculated using GraphPad Prism version 6.0. Error bars show standard deviations. Reproducibility was conﬁrmed by performing the same experiment
three times
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after lentiviral transduction of CCDC6-RET cDNAs with or
without the S904F mutation (Supplementary Fig. 5). Consistently,
Ba/F3 cells expressing CCDC6-RET cDNA with the S904F
mutation showed a greater GI50 to vandetanib (1070 vs. 278.2
nM) than those without the mutation (Fig. 2b). To validate the
results of the cell-based assay, an in vitro kinase assay was per-
formed using puriﬁed RET kinase polypeptides, which showed
that the IC50 of vandetanib was higher in the S904F mutant
(908.5 nM) than in the wild-type kinase (67.82 nM) (Fig. 2c). This
result was consistent with a signiﬁcantly poorer inhibitory con-
stant (Ki) of vandetanib in the S904F mutant (43.09 nM) than in
the wild type (11.57 nM) (Fig. 3a and Supplementary Fig. 6).
An in vitro kinase assay was performed to examine the effect of
the S904F mutation on the kinetic proﬁle of RET kinase toward
synthetic peptide substrates. The results showed that the S904F
mutant had a higher afﬁnity for ATP (Km[ATP]), resulting in an
increased catalytic efﬁciency (kcat/Km[ATP]) (Fig. 3a, b). An even
more dramatic difference was observed for the S904F mutant,
which showed accelerated and enhanced autophosphorylation
kinetics compared with those of the wild-type protein (Fig. 3c).
These results indicate an activating effect of the RET-S904F
mutation, which is consistent with a previous report indicating
that the same mutation is responsible for familial thyroid
cancer12. The positive effect of the S904F mutant on the afﬁnity
for ATP and autophosphorylation of RET kinase may induce
vandetanib resistance by decreasing the relative competitiveness
of the type I inhibitor, vandetanib, against ATP (Supplementary
Fig. 6).
To explore the impact of S904F on the overall RET
conformation, the crystal structure of auto-phosphorylated RET
kinase domain was determined at 2.3 Å and reﬁned to a working
R-value of 19.8% (R-free 23.7%, Supplementary Table 1), with
good model geometry. The overall structure is very similar to the
wild type (PDB code 2IVT). Residues 820–825 are ordered ﬁrst
time compared with previously published RET kinase domain
structures13. The nucleotide pocket is occupied by an adenosine
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Fig. 3 Kinetic and structural properties of the RET-S904F mutant. a Enzyme kinetics parameters of wild type and S904F mutant RET KD proteins. The
kinase assay was performed in triplicate at 25 °C for different incubation times (0, 10, 20, 30, 40, and 50min) using puriﬁed RET KDs, increasing
concentrations of ATP (3.125–400 nM), and serially diluted vandetanib. The assay was initiated by addition of 32P-ATP, and the reaction mixture was
incubated at 30 °C. These experiments were performed independently three times. The data were analyzed using GraphPad Prism version 6.0 to calculate
kinetic parameters, Ki, and IC50 values. b Saturation curve graphed by Michaelis–Menten equation. The graph with standard deviations (shown as error
bars) was generated using GraphPad Prism. cWestern blotting showing the autophosphorylation time course in the wild type and S904F mutant RET KDs.
Phosphorylation of the recombinant puriﬁed RET KDs treated with ATP (5 mM) and MgCl2 (10mM) for 0–80min was detected with the indicated
antibodies. d Comparison of S904F and wild-type RET structures. (Upper) Detail of side chain contacts close to the F904 mutation site of mutant RET
kinase domain (PDB code 6FEK). Selected sidechains are labeled. Bound waters are shown as red spheres and hydrogen-bonds drawn in gray as deﬁned by
Pymol Molecular Graphics System (Schrödinger, LLC, New York, NY). (Middle) Detail of side chain contacts close to the S904 of wild-type RET kinase
domain (PDB code 2IVT), colored as per panel (upper). (Lower) Overlay of the RET core kinase domain wild type and S904F mutant structures omitting
bound waters for clarity
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moiety. Only small differences in side chain positioning are
observed close to the F904 residue. F904 side chain makes Van
der Waals contacts with V906, I927 and the aliphatic portion of
E902, thereby deﬁning a small hydrophobic core absent from wild
type RET (Fig. 3d). This may tether the activation loop more
tightly in both non-phospho- and phospho-RET forms, enhan-
cing the basal level of RET activity.
Decreased thermal stability of the RET kinase-drug complex
induced by the S904F mutation. The Ki and IC50 values for
vandetanib were increased in the S904F mutant at concentrations
several 1000-fold lower than those of ATP (Figs. 2c and 3a). To
further investigate this effect, a thermal shift assay was performed
to examine directly the stability of the enzyme-ligand complex.
This assay determines the drug-induced increase in the melting
temperature (ΔTm) of the puriﬁed RET KD, which reﬂects the
stability of the kinase-ligand complex13.
When the RET protein was phosphorylated, addition of
vandetanib increased the ΔTm of the wild-type RET KD by
6.11± 0.19 °C, consistent with a recent study14. Addition of
vandetanib increased the ΔTm of the S904F RET KD only by 3.76
± 0.17 °C (Fig. 4a and Supplementary Table 2). When the RET
kinase protein was not phosphorylated, the ΔTm increases were
smaller and comparable between the wild type and S904F RET
KDs (Fig. 4a and Supplementary Table 2). These data suggested
that the S904F mutation decreased the afﬁnity for vandetanib in
the KD by reducing the magnitude of thermal stabilization
induced by drug addiction.
Discussion
The present study identiﬁed a secondary S904F mutation con-
ferring resistance to vandetanib in a metastatic LADC harboring a
CCDC6-RET fusion that initially exhibited a response to treat-
ment but later progressed. The RET-S904F mutation was located
in the AL, in which mutations are not linked to drug resistance to
the best of our knowledge. The mutant showed increased ATP
afﬁnity and autophosphorylation activity. These results are con-
sistent with the S904F mutation as a germline oncogenic muta-
tion responsible for the development of familial thyroid cancer
and with the ability of the RET S904F mutant to activate RET
kinase and transform NIH3T3 ﬁbroblasts12. Since vandetanib is a
type I inhibitor that inhibits RET kinase activity in an ATP-
competitive manner, the increased ATP afﬁnity and autopho-
sphorylation activity may be responsible for the resistance
induced by the mutant. Increased ATP afﬁnity underlies the
resistance to type I TKIs of an EGFR kinase mutant with a
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Fig. 4 Decreased thermal stability of the RET kinase-vandetanib complex induced by the S904F mutation. a A thermal shift assay was performed to
determine the drug-induced changes in the melting temperature (ΔTm) of puriﬁed RET KD, which reﬂect the stability of the complex13. Recombinant wild
type or S904F mutant RET KD was generated using previously published methods13. Each protein was dephosphorylated using CIP-phosphatase and then
either used directly (unphosphorylated) or phosphorylated by addition of Mg-ATP, followed by incubation with DMSO or 1 µM vandetanib. Wild type and
S904F mutant RET KDs without drug showed Tm values of 43.00± 0.06 °C and 44.16± 0.04 °C, respectively (Supplementary Table 1). Addition of
vandetanib increased the ΔTm of wild-type RET KD by 6.11± 0.19 °C, whereas it increased the ΔTm of phosphorylated S904F RET KD only by 3.76±0.17 °C.
Unphosphorylated RET KDs showed little or no (ΔTm) increase irrespective of the mutation status (Supplementary Table 1). b Geometry of the hydrogen-
bond network consisting of E734, D771, and R912, which regulates the accessibility of ATP to the nucleotide-binding pocket and active site. The mean
structures of E734, F735, R770, D771, S/F904, pY905, K907, R912, and vandetanib, generated by molecular dynamics simulations of 1 μs × 3 times, are
represented by thick sticks (gray, carbon; blue, nitrogen; orange, phosphorus; red, oxygen; light blue, ﬂuorine; and light pink, bromine). Mean geometry of
the hydrogen-bond network formed by E734, D771, and R912 is depicted by dashed green lines, showing the formation of an E734-R912 hydrogen bond at
an irregular position in the S904F mutant, and the intermediate conformer is likely to be stabilized by this aberrant hydrogen-bond network
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T790M mutation in its ATP-binding cleft15,16. Thus, increased
ATP afﬁnity might be a common mechanism of drug resistance
in oncogenic kinases.
A thermal shift assay in the presence or absence of drug sug-
gested that the S904F mutation is less able to bind vandetanib. The
co-crystal structure of RET kinase in complex with vandetanib
indicates that the mutated residue (F904) does not directly interfere
with vandetanib binding because of its location (Fig. 4b)13.
Therefore, we investigated whether an allosteric effect of the S904F
mutation may result in a conformational change affecting the
stability of the RET kinase-vandetanib complex. Molecular
dynamics (MD) simulation using the human RET KD in complex
with vandetanib17 suggested dynamic coupling pattern differences
in regions of AL and the glycine-rich loop (GRL) between the wild
type and S904F mutant (Supplementary Fig. 7a), concomitantly
with a decrease in the ﬂuctuation of these regions in the S904F
mutant (Supplementary Fig. 7b). The GRL of the RET KD, in
particular the side chain of phenylalanine 735 (F735), has been
reported to regulate the ATP-binding capacity by interconverting
between two conformers, open (ATP-binding competent) and
closed (ATP-binding blocked)18 (Supplementary Fig. 7c). The
mean structures of MD trajectories suggested that the S904F
mutation causes a geometrical change in E734 (in GRL), D771 (in
αC helix), and R912 (in AL) which compose a triad of tethered
residues via salt bridge interaction18 (Fig. 4b). The geometrical
change was associated with the appearance of an additional de
novo conformer represented by a higher energy state (i.e., lower
afﬁnity to vandetanib) than that of the open/closed conformers
(Supplementary Fig. 7d and e). The de novo conformer (designated
as “intermediate”) was suggested to have a protrusion of the side
chain of F735 in the GRL toward the drug-binding site, which
would sterically interfere with the binding of vandetanib (Supple-
mentary Fig. 7c, f and g; and Supplementary Movies 1, 2).
The present results indicated that the secondary S904F muta-
tion located in the AL, and therefore distant from the ATP-
binding site, may exhibit allosteric effects conferring resistance to
vandetanib. The increased ATP afﬁnity and autophosphorylation
activity of the mutant were considered the main factors under-
lying the resistance to the type I inhibitor vandetanib. Loss-of-
tight vandetanib interaction could be inferred from the smaller
thermal melt gains upon drug addition to S904F mutant protein.
The precise mechanisms underlying these allosteric effects remain
largely unclear requiring further clariﬁcation by crystallography
and/or biophysical studies.
Methods
Study oversight. The study was approved by the Institutional Review Boards of
the National Cancer Center. The patient provided written informed consent for the
genetic analysis and participation in the investigator-initiated clinical trial.
Clinical trial. The LURET (Lung Cancer with RET Rearrangement Study; clinical
trial registration number: UMIN000010095, https://upload.umin.ac.jp/) trial
investigated the efﬁcacy of vandetanib in non-small cell lung cancer (NSCLC) with
an oncogenic RET fusion. LURET is coupled with a nation-wide genetic screen,
LC-SCRUM-Japan (Lung Cancer Genomic Sreening Project for Individualized
Medicine in Japan), in which more than 2000 EGFR mutation-negative non-
squamous NSCLC patients were enrolled from >190 hospitals in all 47 prefectures
of Japan for screening of ALK, RET, and ROS1 gene fusions.
For the LURET clinical trial, eligible patients had pathologically conﬁrmed,
locally advanced or metastatic non-squamous NSCLC with RET rearrangement
without EGFR mutations and failed at least one previous chemotherapy. RET
fusion positivity was determined by double positivity in reverse transcriptase-
polymerase chain reaction (RT-PCR) and break-apart ﬂuorescence in situ
hybridization (FISH) assays. Of 34 RET fusion-positive patients detected by RT-
PCR, 19 were enrolled in the clinical trial to study the efﬁcacy of vandetanib. In 17
eligible patients included in the primary analysis, the response rate was 53%. In the
19 registered patients, the disease control rate was 90%. Progression-free survival
was 4.7 months. The details of the clinical trial are described in the published
paper8.
Samples. A patient with lung adenocarcinoma (LADC) harboring a CCDC6-RET
fusion underwent biopsy of pretreated and vandetanib-resistant tumors. Histo-
pathological and immunohistochemical diagnoses were performed. Total RNA was
extracted from grossly dissected, snap-frozen tissue samples using TRIzol (Invi-
trogen, Carlsbad, CA, USA), and its quality was determined using a 2100 Bioa-
nalyzer (Agilent Technologies, Santa Clara, CA, USA). Genomic DNA was
extracted from the same tumors and peripheral blood using the QIAamp DNA
mini kit (Qiagen, Limburg, The Netherlands).
PCR and sanger sequencing. Methods for RT-PCR and Sanger sequencing were
described previously6. Total RNA (500 ng) was reverse-transcribed into cDNA
using Superscript III Reverse Transcriptase (Invitrogen). cDNA (corresponding to
10 ng of total RNA) or 10 ng of genomic DNA was subjected to PCR ampliﬁcation
using KAPA Taq DNA Polymerase (KAPA Biosystems, Woburn, MA, USA). For
detection of the fusion point, the following PCR primers were used: for cDNA
ampliﬁcation, 5′-TGCAGCAAGAGAACAAGGTG-3′ (CCDC6 forward) and 5′-
TGAGAGGCCGTCGTCATAAA-3′ (RET reverse); for genomic DNA ampliﬁca-
tion, 5′-TGTCAAAACTGGCCTCTCTG-3′ (CCDC6 forward) and 5′-GGAACC-
CACAGTCAAGGTCA-3′ (RET reverse). The reactions were carried out in a
thermal cycler under the following conditions: 40 cycles of 95 °C for 30 s, 60 °C for
30 s, and 72 °C for 2 min, with a ﬁnal extension at 72 °C for 10 min. The gene
encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was ampliﬁed to
estimate the efﬁciency of cDNA synthesis in the RT-PCR analysis. PCR products
were directly sequenced in both directions on an ABI 3130xl DNA Sequencer
(Applied Biosystems, Foster City, CA, USA) using the BigDye Terminator kit.
Targeted and whole-exome sequencing. Targeted and whole-exome sequencing
was performed using 1.0 µg of DNA extracted from biopsied tissues. Targeted
genome and exome capture were performed using the Agilent SureSelect kits, NCC
Oncopanel (Catalog No. 931196, Agilent) and Human All Exon V5, respectively.
Sequencing was performed on the Illumina HiSeq 1500 platform using 100 bp
paired-end reads (Illumina). Basic alignment and sequence quality control were
performed using the Picard and Firehose pipelines. The reads were aligned against
the reference human genome from UCSC human genome 19 (Hg19) using the
Burrows Wheeler Aligner Multi-Vision software package. Because duplicate reads
were generated during the PCR ampliﬁcation process, paired-end reads that
aligned to the same genomic positions were removed using SAMtools. Somatic
SNVs were called by the MuTect program, which applies a Bayesian classiﬁer to
allow detection of somatic mutations with low-allele frequency. Somatic insertion/
deletion mutations (indels) were called using the GATK Somatic IndelDetector
(https://software.broadinstitute.org/gatk/). In addition, target sequencing was per-
formed for 10 ng of DNAs using the Ion Ampliseq Cancer Hotspot Panel v2 and
the Ion Proton sequencer (Thermo Fisher Scientiﬁc, Waltham, MA, USA).
Alignment of amino acid sequences. Tyrosine kinases belonging to the RET
superfamily were listed via the Ensembl Genome Browser (www.ensembl.org) and
the human kinome19. The alignments were obtained from Uniprot (http://www.
uniprot.org/) and visualized by Jalview (http://www.jalview.org/).
Immunohistochemistry. Sections (4 µm thick) were deparafﬁnized. Immunohis-
tochemical staining was performed using a Ventana Discovery XT instrument
supplied by Ventana Medical Systems Inc. (Tucson, AZ, USA) according to the
manufacturer’s instructions. The primary antibodies against TTF-1 (SP141) were
purchased from Ventana Medical Systems Inc. (Catalog No. 790-4756, ready to use
without dilution), and thyroglobulin was purchased from Dako (Catalog No.
M078101, Glostrup, Denmark, ready to use without dilution). The reactions were
visualized with 3,3′-diaminobenzidine followed by counterstaining with
hematoxylin.
Cell lines and reagents. NCI-H1299 cells and Ba/F3 cells were provided by
Dr. J.D. Minna of UT Southwestern Medical Center and Dr. Hiroyuki Mano of
University of Tokyo, respectively. 293FT cells and WEHI-3B cells were obtained
from Invitrogen (Carlsbad, CA, USA) and RIKEN BioResource Center (Japan),
respectively. NCI-H1299 and WEHI-3B were cultured in RPMI medium with 10%
fetal bovine serum (FBS). Ba/F3 cells were cultured in RPMI medium containing
10% FBS and 10% WEHI-3B–conditioned medium (a source of interleukin 3
[IL3]), and 293FT cells were cultured in DMEM with 10% FBS. All cells were
incubated at 37 °C in 5% CO2.
Vandetanib was purchased from Selleck (Houston, TX, USA). Primary
antibodies against RET (Catalog No. ab134100) and phospho-Tyr1015 RET
(Catalog No. ab74154) were purchased from Abcam (Cambridge, UK). Antibodies
against phospho-Tyr 905 Ret (Catalog No. 3221), GAPDH (Catalog No. 5174), and
beta-actin (Catalog No. 3700) were purchased from Cell Signaling Technology
(Danvers, MA, USA). Antibodies against phospho-Tyr1062 RET (Catalog No. sc-
20252-R) and total phospho-tyrosine (Catalog No. sc-7020) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
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Construction of lentiviral vectors expressing wild type and S904F mutant
CCDC6-RET cDNA. Full-length wild type and S904F mutant CCDC6-RET cDNAs
were synthesized by FASMAC (Kanagawa, Japan). cDNAs were ligated into pLenti-
6/V5-DEST plasmids (Invitrogen). The integrity of each inserted cDNA was ver-
iﬁed by Sanger sequencing. Expression of cDNA products was conﬁrmed by
immunoblotting of transiently transfected cells.
Lentiviral production and infection. Lentiviruses were generated in 293FT cells
(6 × 106 cells per 10 cm plate) transfected with pLenti-6/V5-DEST plasmid con-
taining either the wild type or S904F mutant CCDC6-RET cDNA and ViraPower
packaging mix (Invitrogen) using the Lipofectamine 3000 reagent (Invitrogen).
Viral supernatants were collected at 42 h after the medium change, and then used
to infect 4.0 × 105 Ba/F3 cells in the presence of 10 μg/ml Polybrene (Sigma-
Aldrich, St Louis, MO, USA) by centrifugation at 3000×g for 150 min at 32 °C.
Following overnight incubation at 37 °C in 5% CO2, the cells were distributed into
24-well plates and selected in medium containing IL3 and 8 μg/ml blasticidin
(Invitrogen) for 1 week. The blasticidin-resistant cells were grown in IL3-free
medium for 2 weeks. The expression of exogenous CCDC6-RET proteins was
conﬁrmed by immunoblotting coupled with Sanger sequencing of RT-PCR pro-
ducts from the cells (Supplementary Fig. 5a, b).
CCDC6-RET phosphorylation assay. NCI-H1299 cells were transiently trans-
fected with 5 μg of plasmid DNA using Lipofectamine 3000. The cells were re-
seeded at 12 h after transfection. After 24 h, the cells were cultured with vehicle or
increasing doses of inhibitors for 6 h. Ba/F3 cells (5.0 × 106) stably expressing wild
type or S904F mutant CCDC6-RET were cultured with vehicle or increasing doses
of inhibitors for 6 h. The cells were lysed in RIPA buffer (1% NP-40, 0.1% sodium
deoxycholate, 50 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1 mM EDTA [pH 8.0],
0.1% SDS, 1 mM Na3VO4, and 10 mM NaF) containing Complete Protease Inhi-
bitor Cocktail (Roche, Mannheim, Germany). Cell lysates were centrifuged at
14,000×r.p.m. for 15 min, and the supernatants were collected. The supernatants
were subjected to SDS-PAGE, followed by immunoblotting onto polyvinylidene
diﬂuoride membranes. The membranes were blocked for 1 h with TBS containing
0.1% Tween 20 (TBST) and 1.0% BSA, and then probed with primary antibodies;
anti-RET (used at 2000-fold dilution), anti-phospho-Tyr1015 RET (used at 500-
fold dilution), anti-phospho-Tyr 905 Ret (used at 1000-fold dilution), anti-GAPDH
(used at 1000-fold dilution), and anti-beta-actin (used at 1000-fold dilution). After
washing with TBST, the membranes were incubated with horseradish peroxidase-
conjugated anti-mouse or anti-rabbit secondary antibodies, and then visualized
with enhanced chemiluminescence reagent (Perkin Elmer, Waltham, MA, USA).
Intensities of signals were quantiﬁed using a LAS3000 imaging system (Quansys
Biosciences, West Logan, UT, USA). Assays were independently performed more
than three times. To determine the half-maximal inhibitory concentration (IC50)
values in the H1299 model, the signal intensities of total and phospho-Y905 of
CCDC6-RET were quantiﬁed using Multi-gauge software (Fujiﬁlm, Tokyo, Japan).
After subtraction of the background, the signal intensity at each dose was stan-
dardized by dividing it by that of the inhibitor-free sample labeled “0”. The mean
ratios of phospho-Y905 to total CCDC6-RET in three independent assays were
plotted with error bars. Uncropped gel data are supplied in the Supplementary
Fig. 8.
Cell viability assays. Twenty-four hours before inhibitor treatment, 2000 Ba/F3
cells stably expressing CCDC6-RET with or without the S904F mutation were
plated in quadruplicate in 96-well plates. Serially diluted inhibitors were added to
the wells. Cell viability was measured at 72 h after drug treatment using the
CellTiter-Glo luminescent cell viability reagent (Promega, Madison, WI, USA) with
EnVision (Perkin Elmer, Waltham, MA, USA). Cell viability was calculated as the
cell count in drug-treated samples relative to that in untreated samples. The data
were displayed graphically using GraphPad Prism version 6.0 (GraphPad Software
Inc., San Diego, CA, USA). Assays were independently repeated more than three
times.
In vitro kinase assay. The recombinant RET kinase domain (KD; amino acids
658–1072) with or without the S904F mutation was expressed by baculovirus in Sf9
insect cells using an N-terminal GST tag (gene accession number: NM_020630). To
determine kinetic constants, RET kinase assays were performed in triplicate at 25 °
C for different incubation times (0, 10, 20, 30, 40, and 50 min) in a ﬁnal volume of
25 μl as follows: 5 μl of diluted active wild type or S904F mutant RET kinase (41.6
ng each); 5 μl of kinase assay buffer (SignalChem); 5 μl of diluted vandetanib
(various concentrations); 5 μl of IGF1Rtide synthetic peptide substrate
(KKKSPGEYVNIEFG) (SignalChem, Richmond, BC, Canada); and 5 μl of radio-
active 32P-ATP cocktail at various concentrations (32P-ATP [Perkin Elmer, Wal-
tham, MA, USA] and cold ATP [SignalChem, Richmond, BC, Canada]). To
determine IC50 values, assays were performed in triplicate for 30 min with 5 µM
ATP. The assay was initiated by addition of 32P-ATP to the reaction mixture,
including kinase assay buffer, serially diluted vandetanib, and IGF1Rtide synthetic
peptide as substrate, and incubated at 30 °C for 20 min. After the incubation
period, the reaction was terminated by spotting 10 μl of the reaction mixture onto a
multiscreen phosphocellulose P81 plate. The multiscreen phosphocellulose P81
plate was washed twice for ~15 min each in 1% phosphoric acid solution. The
radioactivity on the P81 plate was counted in the presence of scintillation ﬂuid in a
TriLux scintillation counter. For each target, blank controls included all assay
components except the corresponding substrate, which was replaced with an equal
volume of assay dilution buffer. The corrected activity for each target was deter-
mined by subtracting the blank control value. Reproducibility was conﬁrmed by
performing the same experiment three times. The data were analyzed using
GraphPad Prism version 6.0 for Mac to calculate kinetic parameters, inhibitory
constant (Ki), and IC50 values.
RET kinase domain S904F mutant X-ray structure determination. Recombi-
nant RET kinase domain RET-KD (residues 705–1013) was expressed in Sf9 cells
using a recombinant baculovirus and puriﬁed by afﬁnity chromoatography as
described previously20. Residues from the kinase insert region (827–840) were
omitted from this construct. Puriﬁed RET mutant protein was then concentrated to
4.5 mg/ml in crystallization buffer (20 mM Tris, pH 8, 100 mM NaCl, 1 mM DTT,
and 1 mM EDTA). Crystals were grown at 16 °C in sitting drops containing 3.4 M
sodium formate, and 0.1 M sodium acetate pH 4.4. All crystals were collected
directly into the cryoprotectant oil, perﬂuoro-polyether (Hampton Research) and
ﬂash-frozen in liquid nitrogen. The data were collected, at the Swiss Light Source
(Supplementary Table 1) and processed using standard data integration and scaling
software. The crystals belong to space group P43212 with a single molecule in the
asymmetric unit. The structure was solved by molecular replacement using
phosphorylated RET-KD-P protein (PDB code 2IVT) as a search model and
omitting ﬂexible regions and phosphotyrosines. The structure was reﬁned using
Phenix.reﬁne21 and rebuilt using Coot22. Electron density is of a good quality. The
RET activation loop is phosphorylated on Tyr 905 sidechains. The structure was
reﬁned at 2.3 Å to an Rwork of 19.8% (and Rfree 23.7%) shown in Supplementary
Table 1.
Thermal shift assay. Wild type and S904F mutant RET KD proteins were
expressed in SF21 cells and puriﬁed using a GST afﬁnity tag as previously
described13. Each protein was dephosphorylated and then either left in its
dephosphorylated state or phosphorylated by addition of ATP/Mg for 90 min at
room temperature. To determine the thermal shifts, recombinant proteins were
incubated with DMSO or 1 µM vandetanib. Sypro-Orange dye (Life Technologies)
was added to each drug treatment, and the thermal shift was measured in a 7500
Fast RT-PCR machine (Applied Biosystems) in a temperature range of 25–90 °C.
Subsequent analysis was performed using Protein Thermal Shift Software v1.2
(Applied Biosystems).
Autophosphorylation assay. The time course of autophosphorylation of recom-
binant puriﬁed RET KD (2.5 μM) was examined in the presence of saturating
concentrations of ATP (5 mM) and MgCl2 (10 mM) for 0–80 min as previously
described18. Reactions were stopped by addition of 4× loading sample buffer
(Invitrogen) with 10% β-mercaptoethanol and boiling for 5 min. Samples were then
loaded onto to a NuPAGE Invitrogen 4–12% Bis-Tris precast gel. Phosphorylation
was detected with the following antibodies: anti-phospho-Tyr1062 RET (used at
3000-fold dilution), anti-phospho- tyrosine (used at 1000-fold dilution), phospho-
Tyr 905 RET (used at 1000-fold dilution), and anti-total RET (used at 1000-fold
dilution), purchased from Cell Signaling Technology. Uncropped gel data are
supplied in Supplementary Fig. 9.
Molecular dynamics (MD) simulation. The initial structural data of vandetanib-
bound RET kinase were obtained from the Protein Data Bank (PDB code: 2IVU).
The structures of disordered loops (residues Leu712–Asp714 and Arg820–Arg844)
were modeled using the Structure Preparation module in the Molecular Operating
Environment (MOE, Chemical Computing Group, Montreal, Canada), version
2013.0823. The initial structural data of ATP-bound RET were obtained from the
PDB (PDB code: 2IVT). The structures of disordered loops (residues
Ile711–Pro715 and Val822–Arg844) were modeled using the Structure Preparation
module in MOE, and β and γ phosphates were modeled using the Builder module
in MOE. The N- and C-termini of all protein models were capped with acetyl and
N-methyl groups, respectively. Titratable residues remained in their dominant
protonation state at pH 7.0. A S904F mutation was introduced into the structure of
wild-type RET using the Structure Preparation module in MOE.
All MD simulations were performed using the GROMACS 4 program24 on
High Performance Computing Infrastructure equipped with NVIDIA Tesla K20
GPGPUs. Both small-molecule compounds (vandetanib and ATP) were optimized,
and the electrostatic potential was calculated at the HF/6–31G* level using the
GAMESS program25, after which the atomic partial charges were obtained by the
RESP approach26. Other parameters for vandetanib and ATP were determined by
the general Amber force ﬁeld (GAFF)27 using the antechamber module of AMBER
Tools 12. The parameters for ATP were as determined by Meagher et al.28. The
Amber ff99SB-ILDN force ﬁeld was used for proteins and ions29, and TIP3P was
used for water molecules30. Water molecules were placed around the complex
model with an encompassing distance of 8 Å to form a 88 × 83 × 72 Å3 periodic box
for the RET-vandetanib complex and a 91 × 86 × 74 Å3 periodic box for the RET-
ATP complex, including ~16,000 water molecules in the RET-vandetanib system
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and 17,000 water molecules in the RET-ATP system. Charge-neutralizing ions were
added to neutralize the system. Electrostatic interactions were calculated using the
particle mesh Ewald (PME) method31 with a cutoff radius of 10 Å. Van der Waals
interactions were cutoff at 10 Å. The P-LINCS algorithm was applied to constrain
all bond lengths32. After energy-minimization of each of the fully solvated systems,
the system was equilibrated for 100 ps at 298 K under NVT conditions and run for
100 ps under NPT conditions at 1 bar, with the heavy atoms of the protein and
compound held in ﬁxed positions. The time constants for the temperature and
pressure couplings to the bath were 0.1 ps and 2 ps, respectively. Each production
run lasted 50 ns at 298 K, maintained using velocity rescaling with a stochastic
term33, and 1 bar, maintained using the Parrinello–Rahman pressure coupling34.
Equilibration and production runs were performed with time steps of 2 fs.
For the RET-ATP system, three independent MD simulations were performed
with different initial velocities (1 μs × 3), resulting in 3 μs simulations. For the RET-
vandetanib system, 15 independent MD simulations were performed with different
initial velocities (50 ns × 15), and an additional 950 ns simulation was performed
for each of three trajectories in which open, closed, and intermediate
conformational states were observed. These simulations were conducted for both
wild type and mutant RET. Snapshots were output every 2 ps to yield
500 snapshots per ns of simulation.
Clustering of MD structures of the RET-vandetanib complex. Conformational
ﬂuctuations of the ATP-binding pocket in the RET-vandetanib complex were
analyzed by focusing on the glycine-rich loop (GRL; 731–737) because its crys-
tallographic B-factors were higher than those of other regions surrounding the
pocket13. In addition, the presence of two distinct conformations of the loop in the
crystal structure18 indicate that it is highly ﬂexible. The conformational states of the
loop and compound were analyzed using intermolecular potential energy terms35.
At even numbers of nanoseconds in the trajectories (e.g., 0, 2, and 4 ns), 2 ns
averages of intermolecular electrostatic and van der Waals potential energies were
calculated for all pairs of compound atoms and amino acids in the GRL (30
compound atoms × 7 residues × 2 = 420 energy terms), and each of the CH3, CH2,
CH, and NH groups was treated as a single atom. These energy terms in 50 ns × 15
trajectories for RET-vandetanib (375 frames) were hierarchically clustered using
the furthest-neighbor method and Euclidian distance, and the trees produced by
the clustering were cut at a height of 0.5 kcal/mol. Almost all frames for the wild-
type-vandetanib complex were clustered into a single category, whereas frames for
the S904F mutant-vandetanib complex were clustered into two categories. The
same method was applied to long time trajectories (1 μs × 3, 1500 frames) for RET-
vandetanib/ATP.
Calculation of the protein-compound binding free energy. The MP-CAFEE
method was used to calculate the protein-compound binding free energy17,36,37.
For each protein-compound complex and solvated compound, a 32 λ parameter set
for the Coulomb and van der Waals interactions was used17, and six independent
simulations were performed with different initial velocities for each λ parameter.
The binding free energy for a single-protein-compound pair was calculated by
performing 384 (= 6 × 32 × 2) simulations. During these simulations, the tem-
perature was maintained at 298 K using the Nose-Hoover thermostat, and the
pressure was maintained at 1 bar using the Berendsen barostat38. The time con-
stants for the temperature and pressure couplings to the bath were 0.3 ps and 1 ps,
respectively. MD simulations for MP-CAFEE were performed on the K computer
(RIKEN, Japan).
Data availability. The authors declare the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles.
Uncropped scans of immunoblots are shown in Supplementary Figs. 8, 9. The
cDNA sequence for the S904F mutant is available in GenBank under the accession
code KU254649. Raw data for targeted and whole-exome sequencing are available
in Integrative Disease Omics Database (https://gemdbj.ncc.go.jp/omics/docs/
others.html) under accession codes TRS001/002 and WES001, respectively. The
S904F structure coordinates and structures factors have been deposited with Pro-
tein Data Bank (PDB) under the accession code 6FEK. All other data are available
from the corresponding author on request.
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